We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MRVL:NASDAQMarvell Technology, Inc. Analysis

Data as of 2026-05-23 - not real-time

$196.33

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Marvell (MRVL) is trading at $196.33, well above its DCF‑derived fair value of $50.13, implying a ~‑24% downside from intrinsic estimates. The stock sits comfortably above its 20‑day ($171.23), 50‑day ($137.50) and 200‑day ($95.91) moving averages, with a bullish MACD crossover and a high RSI of 71, suggesting strong upward momentum but also a potential overbought condition. Revenue is expanding at a robust 22% YoY, driven by a 51% gross margin and a 32.5% profit margin, while cash on hand ($2.64 B) comfortably exceeds dividend needs, reflected in a modest 0.12% yield and a low 7.8% payout ratio.
Recent material news – notably the acquisition of Polariton Technologies to boost optical‑photonics capabilities for AI‑driven data centers and upbeat analyst upgrades reaffirming a "Buy" stance – reinforces the growth narrative. However, the stock’s valuation metrics (PE 64× vs industry 39×, PB 11.6×) and high beta (2.33) underscore significant price risk, especially given the 30‑day volatility of 58% and a max drawdown of 26%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish technical setup (price above all SMAs, MACD bullish)
  • RSI indicating near‑overbought conditions
  • Recent acquisition bolstering AI‑infra positioning

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high margins
  • Integration of Polariton's photonics to capture AI data‑center demand
  • Analyst consensus of strong‑buy and favorable forward EPS guidance

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Fundamentally solid cash flow but elevated valuation multiples
  • High beta and volatility that may temper price appreciation
  • Sustained dividend with low payout ratio supporting shareholder returns

Key Metrics & Analysis

Financial Health

Revenue Growth22.10%
Profit Margin32.58%
P/E Ratio64.2
ROE19.25%
ROA3.94%
Debt/Equity33.48
P/B Ratio11.6
Op. Cash Flow$1.8B
Free Cash Flow$1.4B
Industry P/E39.5

Technical Analysis

TrendBullish
RSI71.2
Support$146.85
Resistance$198.40
MA 20$171.23
MA 50$137.50
MA 200$95.91
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair Value$50.13
Target Price$149.93
Upside/Downside-23.64%
GradeOvervalued
TypeGrowth
Dividend Yield0.12%

Risk Assessment

Beta2.33
Volatility58.34%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.